|

Rein 3D PRINT PERSONALIZE

RECRUITINGN/ASponsored by University Hospital, Bordeaux
Actively Recruiting
PhaseN/A
SponsorUniversity Hospital, Bordeaux
Started2024-05-28
Est. completion2027-06-15
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

The goal of this clinical trial is to compare preoperative information and patient experience using a personalized versus a generic 3D printed models of patients' tumoral kidney before and after nephron-sparing surgery. The main outcome measure will be based on semi-structured interviews with the patient and the carers.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

Patients:

* Adult patients (≥ 18 years of age)
* Scheduled for surgical management by laparoscopic robotic-assisted partial nephrectomy (1st management for a unilateral or bilateral kidney tumor)
* Expressed consent for integration in the UroCCR database
* Expressed consent for participation in the Rein-3D Personalize study
* Patients affiliated or benefiting from social security system

Professionals:

* Professionals working with patients treated in the Urology, Andrology and Renal Transplant - Department of the Bordeaux University Hospital for at least two months prior to the implementation of 3D models
* Free, informed and signed consent

Exclusion Criteria:

Patients

* Metastatic at inclusion
* Previous renal cancer(s)
* Single kidney at time of inclusion
* No preoperative CT scan, or poor-quality CT scan unable to provide reliable 3D modeling
* Person under legal protection (safeguard of justice, guardianship or curatorship)
* Difficulty understanding and expressing oneself in French

Professionals

* Professionals on internship lasting less than 6 months
* Professionals with no contact with patients

Conditions2

CancerTumoral Kidney

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.